Idera Pharmaceuticals: Declaration of Change of Beneficial Ownership (Form 4)







Property Submission

FORM 4

Check this box if you are no longer subject to section 16, the obligations of Form 4 or Form 5 may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN THE EFFECTIVE BENEFICIARIES OF THE SHARES Filed under Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number: 3235-0287 Expires: January 31, 2005 Estimated average charge hours per response…0.5

1. Name and address of reporting person *

DOUGHERTY MICHAEL R

2. Name of issuer and stock symbol or trading symbol
IDERA PHARMACEUTICALS, INC. [IDRA]

5. Relationship between the reporting person(s) and the issuer
(Check all that apply)

_____ Director

_____ 10% Owner

_____ Officer (indicate title below)

_____ Other (specify below)

(Last)

(First)

(Environment)

C/O IDERA PHARMACEUTICALS, INC., 505 EAGLEVIEW BOULEVARD, SUITE 212

3. Date of first transaction (month/day/year)

4. In case of modification, date of filing of the original (month/day/year)

6. Individual or joint/group filing (check applicable row)
_X_ Form filed by a reporting person
___ Form filed by more than one declarant

Table I – Non-derivative securities acquired, sold or beneficially owned

1. Title of guarantee

2. Transaction date (month/day/year)

2A. Deemed execution date, if applicable (month/day/year)

3. Transaction code

4. Securities acquired (A) or transferred (D)

5. Amount of securities beneficially owned as a result of the reported transaction(s)

6. Form of ownership: direct (D) or indirect (I)

7. Nature of Indirect Beneficial Ownership

Coded

V

Rising

(A) or (D)

Price

Table II – Beneficial ownership derivative securities (for exampleputs, calls, warrants, options, convertible securities)
(for exampleputs, calls, warrants, options, convertible securities)

1. Title of derivative title

2. Conversion or exercise price of the derivative security

3. Transaction date (month/day/year)

3A. Deemed execution date, if applicable (month/day/year)

4. Transaction code

5. Number of derivative securities acquired (A) or sold (D)

6. Exercise date and expiry date

7. Title and amount of the securities underlying the derivative securities

8. Price of derivative securities

9. Number of derivative securities beneficially owned as a result of reported transactions

10. Form of ownership of derivative securities: direct (D) or indirect (I)

11. Nature of Indirect Beneficial Ownership

Coded

V

(A)

(D)

Exercise date

Expiration date

Title

Amount or number of shares

Reporting owners

Name/address of declaring owner Relationships

Director

10% Owner

Officer

Other

DOUGHERTY MICHAEL R
C/O IDERA PHARMACEUTICALS, INC.
505 EAGLEVIEW BOULEVARD, UNIT 212
EXTON, PA19341

Signatures

/s/ Michael R. Dougherty

2022-07-06

**Signature of declaring person

Date

Explanation of answers:

If the form is completed by several declarants, see

Section 5(b)(v).

(**) Intentional misrepresentation or omission of facts are federal criminal offenses. See

18 USC 1001 and 15 USC 78ff(a).

(1)

These shares were issued to the reporting person pursuant to its election under the issuer’s directors’ compensation program to receive common shares in lieu of a cash retainer. Note: Submit three copies of this form, one of which must be manually signed. If space is insufficient, See

Instruction 6 for the procedure. Potential individuals who need to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Disclaimer Idera Pharmaceuticals Inc. published this content on July 06, 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unmodified, onJul 06, 2022 20:33:06 UTC

.

Public now 2022

All news about IDERA PHARMACEUTICALS, INC.

Analyst Recommendations for IDERA PHARMACEUTICALS, INC.



Sales

Net revenue

Net debt
P/E ratio
Yield Capitalization
23.3 million
23.3 million
EV / Sales -1
EV / Sales 0 # of employees
13 Floating

77.1%

Chart IDERA PHARMACEUTICALS, INC.









Idera Pharmaceuticals, Inc. Technical Analysis Chart |  MarketScreener

Idera Pharmaceuticals, Inc. Technical Analysis Chart | MarketScreener

Trending Technical Analysis IDERA PHARMACEUTICALS, INC.
Short term Middle term
Long term Tendencies Bearish Neutral

Bearish


Please enable JavaScript in your browser settings to use dynamic graphics. Medium consensus
Number of analysts
0 Last closing price
0.44
Average target price Average Spread / Target

Please enable JavaScript in your browser settings to use dynamic graphics.


Comments are closed.